$JSDA

Jones Soda Q1 Loss Narrows Y/Y, Expenses Reduce, Revenues Fall 7.8%

JSDA trims Q1 losses with cost cuts and HD9 growth, but revenue slips 7.8% amid tough comps and rising promotional expenses.

Original reporting
Zacks Commentary · Zacks Equity Research
Published May 22, 2025, 3:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 23, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jones Soda Q1 Loss Narrows Y/Y, Expenses Reduce, Revenues Fall 7.8% — source image
Decision brief

The 30-second read

$JSDANeutralMed
01

Why it matters

The company's efforts to reduce costs improved profitability, but declining revenues suggest challenges in sales growth, possibly affecting future profitability.

02

Market read

The news is moderately relevant to investors focusing on small-cap consumer stocks, with potential short-term trading implications.

03

What to watch

Potential seasonal effects or promotional campaigns not accounted for could influence future performance.

Relevance 6/10Timing: short-term (next 1-2 weeks)

Background

Jones Soda reported Q1 earnings showing narrowed losses due to expense reductions, but revenues fell 7.8%, impacted by tough comparisons and rising promotional costs.

Company-level read

Ticker impact

$JSDANeutralMedium confidence
Context

Jones Soda's Q1 earnings report indicates a narrowing loss due to cost reductions and growth in certain segments, but revenue decline suggests ongoing challenges.

Expected impact

Limited immediate impact; potential for short-term stabilization, but revenue decline may exert downward pressure in the medium term.

Evidence & confidence

Cost reductions improved margins, but revenue decline signals underlying demand issues, leading to cautious outlook.

Market effects

The consumer beverage sector may face continued pressure due to revenue challenges among small-cap players.

Limited regional impact; primarily affects US-based small-cap stocks.

Negligible; company-specific news with minimal global implications.

Counterpoint

Revenue decline might be a temporary issue; cost management improvements could lead to margin expansion if sales rebound.

Key entities

  • Jones Soda Co.

    A beverage company specializing in sodas and related products.

Related articles

$JSDAMedAI 8/10

Jones Soda Reports Revenue of $10.2 Million for Q2 2026, Up 108%

Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) reported Q2 2026 revenue of $10.2M, up 107.8% year over year, despite about $2M of expected shipments shifting into Q3. Gross margin fell to 27.5% from 33.3%. Management raised FY2026 net revenue growth to over 80% (revenue above $45M) and expects positive Adjusted EBITDA. Conference call set for Aug. 13, 2026.

$SFLMedAI 8/10

Newbuild order for two very large ammonia acriers in combination with long term time charters

SFL Corporation ordered two 93,000 cbm ammonia carriers for $216 million, deliverable in 2028. The company also secured long-term charters with an oil major, adding $162 million to its backlog. CEO Ole B. Hjertaker highlighted the investment's accretive nature and the charterer's investment-grade status. The total fixed-rate charter backlog for 2026 exceeds $1.3 billion.

$CVXLow

Chevron announces senior leadership changes

Chevron (CVX) announced senior leadership changes effective January 1, 2027. Mark Nelson will focus on strategy and business development, Eimear Bonner will lead Oil, Products & Gas, Jeff Gustavson will become CFO, and Brent Gros will head New Energies and AI strategy. CEO Mike Wirth praised the new leaders' expertise and commitment.

$RAREHighAI 9/10

Ultragenyx agrees to sell voucher for US$210M

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.

$SLBMed

How New Energy Contracts Will Impact SLB (SLB) Stock

SLB (SLB) secured multi-year energy contracts with Aramco and ExxonMobil, expanding its backlog in onshore and deepwater infrastructure. Analysts project $43.0b revenue and $5.5b earnings by 2029, with potential upside. The company's focus on digital and data center solutions is seen as a driver for higher revenue.